Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma

Cancer

Volumn 119, Issue 11, 2013, Pages 1985-1993

  Chen, Zheng ^a,b   Saad, Rama ^a,c   Jia, Peilin ^a   Peng, Dunfa ^a   Zhu, Shoumin ^a   Washington, M Kay ^a   Zhao, Zhongming ^a   Xu, Zekuan ^b   El Rifai, Wael ^a,d,e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c The American University in Cairo   (Egypt)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

esophageal adenocarcinoma; gastric adenocarcinoma; microarray; microRNA; prognosis

Indexed keywords

MICRORNA; MICRORNA 133B; MICRORNA 146B 5P; MICRORNA 148A; MICRORNA 200A; MICRORNA 31; MICRORNA 375; MICRORNA 451; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; UPREGULATION; VALIDATION STUDY;

ADENOCARCINOMA; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878016872     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28002     Document Type: Article

References (60)

1. Parkin DM,. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-543.
2. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009; 125: 666-673.
3. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E,. Gastric cancer. Crit Rev Oncol Hematol. 2009; 71: 127-164.
4. Marusawa H, Chiba T,. Helicobacter pylori-induced activation-induced cytidine deaminase expression and carcinogenesis. Curr Opin Immunol. 2010; 22: 442-447.
5. Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007; 13: 5841-5846.
6. Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J,. Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol. 2006; 59: 128-138.
7. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA,. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012; 30: 3507-3515.
8. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005; 23: 4330-4337.
9. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D,. Explaining gastric cancer survival differences among European countries. Int J Cancer. 2004; 109: 737-741.
10. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007; 99: 545-557.
11. Peek RM Jr, Fiske C, Wilson KT,. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev. 2010; 90: 831-858.
12. Polk DB, Peek RM Jr,. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10: 403-414.
13. Shaheen N, Ransohoff DF,. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA. 2002; 287: 1982-1986.
14. Wang J, Wang Q, Liu H, Hu B, Zhou W, Cheng Y,. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett. 2010; 297: 137-143.
15. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
16. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-833.
17. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104: 16170-16175.
18. Cairo S, Wang Y, de Reynies A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A. 2010; 107: 20471-20476.
19. Paranjape T, Slack FJ, Weidhaas JB,. MicroRNAs: tools for cancer diagnostics. Gut. 2009; 58: 1546-1554.
20. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA,. MicroRNAs in cancer: from bench to bedside. Adv Cancer Res. 2010; 108: 113-157.
21. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58: 1375-1381.
22. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010; 11: 136-146.
23. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al. Mathematical formulae for the prediction of the residual beta cell function during the first 2 years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 1995; 45: 486-490.
24. Peltier HJ, Latham GJ,. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008; 14: 844-852.
25. el-Rifai W, Powell SM,. Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma. Surg Oncol Clin North Am. 2002; 11: 273-291, viii.
26. Schonrock N, Harvey RP, Mattick JS,. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res. 2012; 111: 1349-1362.
27. Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010; 51: 836-845.
28. Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond). 2011; 121: 437-447.
29. Pohl H, Welch HG,. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97: 142-146.
30. Tahara E,. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer. 1995; 75 (6 suppl): 1410-1417.
31. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104: 488-492.
32. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ,. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 657-663.
33. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T,. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133: 647-658.
34. Medina PP, Nolde M, Slack FJ,. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467: 86-90.
35. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299: 425-436.
36. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell. 2010; 18: 282-293.
37. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K,. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010; 39: 493-506.
38. Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010; 127: 2804-2814.
39. Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009; 125: 345-352.
40. Hu G, Chen D, Li X, Yang K, Wang H, Wu W,. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 10: 190-197.
41. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ,. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011; 8: 1381-1389.
42. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009; 69: 5776-5783.
43. Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012; 33: 551-560.
44. Geraldo MV, Yamashita AS, Kimura ET,. MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. Oncogene. 2012; 31: 1910-1922.
45. Ding L, Xu Y, Zhang W, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010; 20: 784-793.
46. Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010; 70: 2339-2349.
47. Zheng B, Liang L, Wang C, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011; 17: 7574-7583.
48. Zhang H, Li Y, Huang Q, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011; 18: 1702-1710.
49. Zhang Y, Guo J, Li D, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol. 2010; 27: 685-689.
50. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009; 137: 1032-1046.
51. Uribesalgo I, Ballare C, Di Croce L,. Polycomb regulates NF-kappaB signaling in cancer through miRNA. Cancer Cell. 2012; 21: 5-7.
52. Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010; 70: 1906-1915.
53. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB,. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30: 2644-2658.
54. Bitarte N, Bandres E, Boni V, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011; 29: 1661-1671.
55. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010; 70: 5226-5237.
56. Hu X, Schwarz JK, Lewis JS Jr, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010; 70: 1441-1448.
57. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011; 17: 1627-1635.
58. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10: 593-601.
59. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ,. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97: 853-861.
60. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009; 15: 5744-5752.